Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9295657 | ENDO OPERATIONS | Epinephrine formulations |
Mar, 2035
(10 years from now) | |
US9119876 | ENDO OPERATIONS | Epinephrine formulations |
Mar, 2035
(10 years from now) | |
US10130592 | ENDO OPERATIONS | Epinephrine formulations |
Mar, 2035
(10 years from now) | |
US11083698 | ENDO OPERATIONS | Epinephrine compositions and containers |
Mar, 2039
(14 years from now) | |
US10653646 | ENDO OPERATIONS | Epinephrine compositions and containers |
Mar, 2039
(14 years from now) | |
US11207280 | ENDO OPERATIONS | Epinephrine compositions and containers |
Mar, 2039
(14 years from now) |
Drugs and Companies using EPINEPHRINE ingredient
Market Authorisation Date: 07 December, 2012
Treatment: Emergency treatment of allergic reactions (type i), including anaphylaxis; To increase mean arterial blood pressure in adult patients with hypotension associated with septic shock
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7718640 | ENDO OPERATIONS | Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels |
Mar, 2027
(2 years from now) | |
US8338395 | ENDO OPERATIONS | Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels |
May, 2027
(2 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Mar 05, 2017 |
Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient
Market Authorisation Date: 05 March, 2014
Treatment: Testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; Primary hypogonadism (congenital or acquired); Hypogonadotropic hypog...
Dosage: INJECTABLE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10869845 | ENDO OPERATIONS | Ephedrine compositions and methods |
Jan, 2040
(15 years from now) |
Drugs and Companies using EPHEDRINE SULFATE ingredient
Market Authorisation Date: 22 April, 2022
Treatment: NA
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6319913 | ENDO OPERATIONS | Penetration enhancing and irritation reducing systems |
Nov, 2018
(5 years ago) | |
US6579865 | ENDO OPERATIONS | Penetration enhancing and irritation reducing systems |
Nov, 2018
(5 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Dec 29, 2013 |
Drugs and Companies using TESTOSTERONE ingredient
Market Authorisation Date: 29 December, 2010
Treatment: Testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone
Dosage: GEL, METERED
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5962501 | ENDO OPERATIONS | Enantiomer of carbazole derivative as 5-HT1-like agonists |
Dec, 2013
(10 years ago) | |
US5616603 | ENDO OPERATIONS | Enantiomers of carbazole derivatives as 5-HT1 -like agonists |
Apr, 2014
(10 years ago) | |
US5637611 | ENDO OPERATIONS | Medicaments |
Jun, 2014
(10 years ago) | |
US5827871 | ENDO OPERATIONS | Medicaments 1,2,3,4-tetrahydrocarbazoles and 5-HT1 agonist use thereof |
Oct, 2015
(8 years ago) | |
US5464864 | ENDO OPERATIONS | Use of tetrahydrocarbazone derivatives as 5HT1 receptor agonists |
Nov, 2015
(8 years ago) |
Drugs and Companies using FROVATRIPTAN SUCCINATE ingredient
Market Authorisation Date: 08 November, 2001
Treatment: Acute treatment of migraine attacks with or without aura in adults
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6592903 | ENDO OPERATIONS | Nanoparticulate dispersions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate |
Sep, 2020
(3 years ago) | |
US7101576 | ENDO OPERATIONS | Nanoparticulate megestrol formulations |
Apr, 2024
(4 months ago) | |
US9101549 | ENDO OPERATIONS | Nanoparticulate megestrol formulations |
Apr, 2024
(4 months ago) | |
US9040088 | ENDO OPERATIONS | Nanoparticulate megestrol formulations |
Apr, 2024
(4 months ago) | |
US9101540 | ENDO OPERATIONS | Nanoparticulate megestrol formulations |
Apr, 2024
(4 months ago) | |
US9107827 | ENDO OPERATIONS | Nanoparticulate megestrol formulations |
Apr, 2024
(4 months ago) |
Drugs and Companies using MEGESTROL ACETATE ingredient
Market Authorisation Date: 05 July, 2005
Treatment: Treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (aids)
Dosage: SUSPENSION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8940714 | ENDO OPERATIONS | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
Feb, 2024
(6 months ago) | |
US7404489 | ENDO OPERATIONS | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
Mar, 2024
(5 months ago) | |
US9415007 | ENDO OPERATIONS | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
Jul, 2024
(a month ago) | |
US7879349 | ENDO OPERATIONS | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
Aug, 2024
(a month ago) | |
US7229636 | ENDO OPERATIONS | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
Aug, 2024
(a month ago) | |
US8003353 | ENDO OPERATIONS | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
Aug, 2024
(a month ago) |
Drugs and Companies using CYANOCOBALAMIN ingredient
Market Authorisation Date: 31 January, 2005
Treatment: Cyanocobalamin administration through nasal infusion; Supplement for vitamin b12 deficiencies; Nasal administration of cyanocobalamin
Dosage: SPRAY, METERED
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8871779 | ENDO OPERATIONS | Process for preparing morphinan-6-one products with low levels of α,β-unsaturated ketone compounds |
Nov, 2029
(5 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5958456 | ENDO OPERATIONS | Controlled release formulation (albuterol) |
Sep, 2013
(11 years ago) | |
US5662933 | ENDO OPERATIONS | Controlled release formulation (albuterol) |
Sep, 2013
(11 years ago) | |
US8329216 | ENDO OPERATIONS | Oxymorphone controlled release formulations |
Feb, 2023
(1 year, 7 months ago) | |
US7276250 | ENDO OPERATIONS | Sustained release formulations of oxymorphone |
Feb, 2023
(1 year, 7 months ago) | |
US8309112 | ENDO OPERATIONS | Coatings for implantable medical devices comprising hydrophilic substances and methods for fabricating the same |
Feb, 2023
(1 year, 7 months ago) | |
US8808737 | ENDO OPERATIONS | Method of treating pain utilizing controlled release oxymorphone pharmaceutical compositions and instruction on dosing for renal impairment |
Jun, 2027
(2 years from now) |
Drugs and Companies using OXYMORPHONE HYDROCHLORIDE ingredient
Market Authorisation Date: 22 June, 2006
Treatment: Relief of moderate to severe pain; Dose modification for renal impairment
Dosage: TABLET, EXTENDED RELEASE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5891086 | ENDO OPERATIONS | Needle-less injector |
Jul, 2014
(10 years ago) | |
US6681810 | ENDO OPERATIONS | Filling device for a needleless injector cartridge |
Dec, 2015
(8 years ago) | |
US6174304 | ENDO OPERATIONS | Filling device for a needless injector cartridge |
Dec, 2015
(8 years ago) | |
US5957886 | ENDO OPERATIONS | Spring-Powered dispensing device |
Mar, 2016
(8 years ago) | |
US6251091 | ENDO OPERATIONS | Needleless injector drug capsule and filling method |
Dec, 2016
(7 years ago) | |
US6135979 | ENDO OPERATIONS | Spring-powered dispensing device for medical purposes |
Mar, 2017
(7 years ago) | |
US6280410 | ENDO OPERATIONS | Method of filling a drug capsule and article produced thereby |
Mar, 2017
(7 years ago) | |
US8343130 | ENDO OPERATIONS | Needleless injector |
Oct, 2022
(1 year, 10 months ago) | |
US8491524 | ENDO OPERATIONS | Needleless injector drug capsule and a method for filling thereof |
Nov, 2022
(1 year, 9 months ago) | |
US8241244 | ENDO OPERATIONS | Needleless injector drug capsule and a method for filling thereof |
Nov, 2022
(1 year, 9 months ago) | |
US8267903 | ENDO OPERATIONS | Casing |
Mar, 2023
(1 year, 5 months ago) | |
US8118771 | ENDO OPERATIONS | Needleless injector drug capsule and a method for filling thereof |
Aug, 2023
(1 year, 29 days ago) | |
US8287489 | ENDO OPERATIONS | Device for readying a needle free injector for delivery |
Dec, 2024
(2 months from now) | |
US8241243 | ENDO OPERATIONS | Needleless injector drug capsule and a method for filling thereof |
Dec, 2025
(1 year, 3 months from now) | |
US7901385 | ENDO OPERATIONS | Casing |
Jul, 2026
(1 year, 10 months from now) | |
US7776007 | ENDO OPERATIONS | Device for readying a needle free injector for delivery |
Nov, 2026
(2 years from now) |
Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient
Market Authorisation Date: 26 November, 2013
Treatment: NA
Dosage: INJECTABLE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8062652 | ENDO OPERATIONS | Compositions and methods for treating precocious puberty |
Jun, 2026
(1 year, 9 months from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity(ODE) | May 03, 2014 |
Drugs and Companies using HISTRELIN ACETATE ingredient
Market Authorisation Date: 03 May, 2007
Treatment: Method of treatment of children with central precocious puberty
Dosage: IMPLANT
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8178518 | ENDO OPERATIONS | Pharmaceutical composition |
Apr, 2023
(1 year, 4 months ago) | |
US7935690 | ENDO OPERATIONS | Pharmaceutical composition |
Apr, 2023
(1 year, 4 months ago) | |
US7608605 | ENDO OPERATIONS | Pharmaceutical composition |
Apr, 2023
(1 year, 4 months ago) | |
US7608606 | ENDO OPERATIONS | Pharmaceutical composition |
Apr, 2023
(1 year, 4 months ago) | |
US8063029 | ENDO OPERATIONS | Pharmaceutical composition |
Apr, 2023
(1 year, 4 months ago) | |
US7608609 | ENDO OPERATIONS | Pharmaceutical composition |
Apr, 2023
(1 year, 4 months ago) | |
US7608608 | ENDO OPERATIONS | Pharmaceutical composition |
Apr, 2023
(1 year, 4 months ago) | |
US7608607 | ENDO OPERATIONS | Pharmaceutical composition |
Apr, 2023
(1 year, 4 months ago) | |
US7608610 | ENDO OPERATIONS | Pharmaceutical composition |
Apr, 2023
(1 year, 4 months ago) | |
US7320968 | ENDO OPERATIONS | Pharmaceutical composition |
Jan, 2025
(4 months from now) |
Drugs and Companies using TESTOSTERONE ingredient
Market Authorisation Date: 31 October, 2002
Treatment: Method for administration of testosterone
Dosage: GEL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9981006 | ENDO OPERATIONS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(10 years from now) | |
US9962422 | ENDO OPERATIONS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(10 years from now) | |
US9925233 | ENDO OPERATIONS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(10 years from now) | |
US9925234 | ENDO OPERATIONS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(10 years from now) | |
US9968649 | ENDO OPERATIONS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(10 years from now) | |
US9974827 | ENDO OPERATIONS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(10 years from now) | |
US10010575 | ENDO OPERATIONS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(10 years from now) | |
US9375478 | ENDO OPERATIONS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(10 years from now) | |
US9744239 | ENDO OPERATIONS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(10 years from now) | |
US9744209 | ENDO OPERATIONS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(10 years from now) | |
US9687526 | ENDO OPERATIONS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(10 years from now) | |
US9919026 | ENDO OPERATIONS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(10 years from now) | |
US9750785 | ENDO OPERATIONS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(10 years from now) | |
US9937223 | ENDO OPERATIONS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(10 years from now) |
Drugs and Companies using VASOPRESSIN ingredient
Market Authorisation Date: 17 April, 2014
Treatment: To increase blood pressure in adults with vasodilatory shock (e.g., post-cardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines
Dosage: SOLUTION